Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Clinical trial NCT07110103 · RECRUITING
Trial details
- NCT number
- NCT07110103
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-31
- Primary completion
- 2027-03-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.